Upcoming Presentations, New Studies, and Stock Price Movements - Research Report on WellPoint, GSK, Forest Laboratories, Intuitive Surgical, and Cubist Pharmaceuticals

Mon Nov 11, 2013 8:01am EST

* Reuters is not responsible for the content in this press release.

Upcoming Presentations, New Studies, and Stock Price Movements - Research Report on WellPoint, GSK, Forest Laboratories, Intuitive Surgical, and Cubist Pharmaceuticals

PR Newswire

NEW YORK, November 11, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting WellPoint, Inc. (NYSE: WLP), GlaxoSmithKline plc (ADR) (NYSE: GSK), Forest Laboratories, Inc. (NYSE: FRX), Intuitive Surgical, Inc. (NASDAQ: ISRG), and Cubist Pharmaceuticals Inc. (NASDAQ: CBST). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

WellPoint, Inc. Research Report

On November 5, 2013, WellPoint, Inc. (WellPoint) announced that the Company's senior management is scheduled to present at the 2013 Credit Suisse Healthcare Conference on November 12, 2013, at 10:30 a.m. MST (12:30 p.m. EST). The Company added that interested parties may listen to a webcast of the presentation by visiting the Company website and selecting the "Investors" link. A replay of the webcast will also be available on WellPoint's website for two weeks following the presentation. The Full Research Report on WellPoint, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/64cd_WLP]

GlaxoSmithKline plc (ADR) Research Report

On November 4, 2013, GlaxoSmithKline plc (ADR) (GSK) announced the results of a Phase III study of its HPV vaccine, Cervarix [Human papillomavirus (HPV) (types 16 and 18) vaccine, recombinant], which showed that two doses of the vaccine in girls aged 9 to 14 years provide an immunogenicity matching the currently licensed three-dose schedule in 15 to 25 year olds. GSK reported that the results corroborate the findings of an earlier proof of concept study, HPV-048, which also assessed the immunogenicity of Cervarix compared to its three-dose schedule and demonstrated that the immunogenicity of two doses of Cervarix in 9 to 14 year old girls is comparable to that seen with three doses in 15 to 25 year old girls for both vaccine HPV types 16 & 18 and for non-vaccine types 31 & 45, throughout the four-year study period. GSK further informed that the vaccine is currently only approved in the EU for use in females from the age of nine years, administered according to a three-dose schedule (vaccine at months 0, one and six) for the prevention of premalignant genital (cervical, vulvar, and vaginal) lesions and cervical cancer related to certain HPV types. On August 7, 2013, GSK had submitted a variation to the current Marketing Authorisation to the European Medicines Agency to add administration of the vaccine according to a two-dose schedule (0, 6 months) in girls aged 9 to 14 years old for the prevention of premalignant genital (cervical, vulvar and vaginal) lesions and cervical cancer causally related to certain oncogenic HPV types. The Full Research Report on GlaxoSmithKline plc (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/2a35_GSK]

Forest Laboratories, Inc. Research Report

On November 6, 2013, Forest Laboratories, Inc.'s (Forest Laboratories) stock rose 1.07%, ending the day at $47.41. Over the previous three trading sessions, shares of Forest Laboratories gained 0.55%, compared to the S&P 500 which gained 0.50% during the same period. The Full Research Report on Forest Laboratories, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/ea24_FRX]

Intuitive Surgical, Inc. Research Report

On November 4, 2013, Intuitive Surgical, Inc. (Intuitive Surgical) announced that a new study, published in the October 2013 issue of The Annals of Thoracic Surgery, comparing open surgery, video-assisted thoracic surgery (VATS) and robotic-assisted surgery to remove diseased lung tissue found that robotic-assisted surgery is associated with significantly lower death rates, lower overall complication rates, and shorter hospital stays compared with open surgery. Further, Intuitive Surgical informed that researchers concluded that robotic-assisted surgery is an appropriate alternative to VATS. Lastly, Intuitive Surgical informed that researchers noted the rise in use of robotic-assisted thoracic surgery in recent years, which has increased over the study period from 0.2% of all procedures in 2008 to 3.4% of procedures in 2010. The Full Research Report on Intuitive Surgical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/5f98_ISRG]

Cubist Pharmaceuticals Inc. Research Report

On November 6, 2013, Cubist Pharmaceuticals Inc.'s (Cubist Pharmaceuticals) stock declined 1.05%, ending the day at $62.10. Over the previous three trading sessions, shares of Cubist Pharmaceuticals have gained 0.26%, compared to the Nasdaq Composite which gained 0.25% during the same period. The Full Research Report on Cubist Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/92f2_CBST]

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.analystscorner.com/

SOURCE Analysts' Corner

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.